Table 3.
Selected baseline comorbidities
| Comorbidity | ITT population [n (%)]a |
CE population [n (%)] |
||
|---|---|---|---|---|
| Solithromycin 800/400 mg (N = 65) | Levofloxacin 750 mg (N = 67) | Solithromycin 800/400 mg (N = 55) | Levofloxacin 750 mg (N = 58) | |
| Any | 39 (60.0) | 34 (50.7) | 34 (61.8) | 30 (51.7) |
| COPD (emphysema, chronic bronchitis) | 16 (24.6) | 11 (16.4) | 14 (25.5) | 9 (15.5) |
| Diabetes mellitus | 15 (23.1) | 15 (22.4) | 13 (23.6) | 14 (24.1) |
| Asthma (reactive airway disease) | 15 (23.1) | 11 (16.4) | 14 (25.5) | 10 (17.2) |
| Hepatitis C | 3 (4.6) | 1 (1.5) | 3 (5.5) | 1 (1.7) |
| Other chronic pulmonary disease | 1 (1.5) | 1 (1.5) | 1 (1.8) | 1 (1.7) |
a
n, number of patients with selected comorbidities; N, total number of patients in the population; %, 100 × (n/N).